INTRA-ARTICULAR MM-II, A NOVEL SUSPENSION OF LARGE EMPTY MULTILAMELLAR LIPOSOMES, IN PAINFUL KNEE OSTEOARTHRITIS: A 26 WEEK PHASE 2B RANDOMIZED TRIAL

被引：0

作者：

Conaghan, P. G. ^{[1
]}

Rovsing, H. ^{[2
]}

Lau, E. ^{[3
]}

Boll, S. L. ^{[4
]}

Brahmachari, B. ^{[5
]}

Chou, R. C. ^{[5
]}

Joshi, T. ^{[5
]}

Wechsler, R. ^{[6
]}

Yao, S. L. ^{[5
]}

Weiner, S. ^{[5
]}

Bihlet, A. R. ^{[7
]}

Schnitzer, T. ^{[8
]}

机构：

[1] Univ Leeds, Leeds Inst Rheumat & Musculoskeletal Med, Leeds, W Yorkshire, England

[2] Sanos Clin, Gandrup, Denmark

[3] Hong Kong Ctr Clin Res, Hong Kong, Peoples R China

[4] Sanos Clin, Vejle, Denmark

[5] Sun Pharmaceut Inc, Princeton, NJ USA

[6] Moebius Med Ltd, Tel Aviv, Israel

[7] NBCD, Soborg, Denmark

[8] Northwestern Univ, Feinberg Sch Med, Chicago, IL USA

来源：

ANNALS OF THE RHEUMATIC DISEASES | 2023年 / 82卷

关键词：

Osteoarthritis; Clinical Trials;

D O I：

10.1136/annrheumdis-2023-eular.5397

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

POS0106

引用

页码：266 / 267

页数：2

共 48 条

[21] CLINICAL OUTCOMES FROM A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2 STUDY OF A NOVEL, INTRA-ARTICULAR, INJECTABLE, WNT PATHWAY INHIBITOR (SM04690) FOR THE TREATMENT OF KNEE OSTEOARTHRITIS: WEEK 26 INTERIM ANALYSIS
Yazici, Y.
Gibofsky, A.
Lane, N. E.
Skrepnik, N.
Armas, E.
Swearingen, C. J.
DiFrancesco, A.
Tambiah, J. R.
McAlindon, T. E.
ANNALS OF THE RHEUMATIC DISEASES, 2017, 76 : 985 - 986
[22] Results from a 52 Week Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of a Novel, Intra-Articular, Wnt Pathway Inhibitor (SM04690) for the Treatment of Knee Osteoarthritis
Yazici, Yusuf
McAlindon, Timothy E.
Gibofsky, Allan
Lane, Nancy E.
Clauw, Daniel J.
Armas, Eddie
Skrepnik, Nebojsa
Swearingen, Christopher J.
DiFrancesco, Anita
Tambiah, Jeymi
Hochberg, Marc
ARTHRITIS & RHEUMATOLOGY, 2017, 69
[23] THE NOVEL, INTRA-ARTICULAR CLK/DYRK1A INHIBITOR LORECIVIVINT (SM04690), A WNT PATHWAY MODULATOR, IMPROVED RESPONDER OUTCOMES IN SUBJECTS WITH KNEE OSTEOARTHRITIS: A POST HOC ANALYSIS FROM A PHASE 2B TRIAL
Tambiah, J.
Kennedy, S.
Swearingen, C.
Yazici, Y.
OSTEOPOROSIS INTERNATIONAL, 2020, 31 (SUPPL 1) : S45 - S46
[24] Phase II multicenter randomized controlled clinical trial on the efficacy of intra-articular injection of autologous bone marrow mesenchymal stem cells with platelet rich plasma for the treatment of knee osteoarthritis
José María Lamo-Espinosa
Juan F. Blanco
Mikel Sánchez
Victoria Moreno
Froilán Granero-Moltó
Fermín Sánchez-Guijo
Íñigo Crespo-Cullel
Gonzalo Mora
Diego Delgado San Vicente
Orlando Pompei-Fernández
Jesús Dámaso Aquerreta
Jorge María Núñez-Córdoba
María Vitoria Sola
Andrés Valentí-Azcárate
Enrique J. Andreu
María del Consuelo del Cañizo
Juan Ramón Valentí-Nin
Felipe Prósper
Journal of Translational Medicine, 18
[25] Phase II multicenter randomized controlled clinical trial on the efficacy of intra-articular injection of autologous bone marrow mesenchymal stem cells with platelet rich plasma for the treatment of knee osteoarthritis
Lamo-Espinosa, Jose Maria
Blanco, Juan F.
Sanchez, Mikel
Moreno, Victoria
Granero-Molto, Froilan
Sanchez-Guijo, Fermin
Crespo-Cullel, Inigo
Mora, Gonzalo
San Vicente, Diego Delgado
Pompei-Fernandez, Orlando
Aquerreta, Jesus Damaso
Nunez-Cordoba, Jorge Maria
Vitoria Sola, Maria
Valenti-Azcarate, Andres
Andreu, Enrique J.
del Consuelo del Canizo, Maria
Valenti-Nin, Juan Ramon
Prosper, Felipe
JOURNAL OF TRANSLATIONAL MEDICINE, 2020, 18 (01)
[26] RESULTS FROM A 52-WEEK RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2 STUDY OF A NOVEL, INTRA-ARTICULAR WNT PATHWAY INHIBITOR (SM04690) FOR THE TREATMENT OF KNEE OSTEOARTHRITIS
Yazici, Y.
McAlindon, T. E.
Gibofsky, A.
Lane, N. E.
Clauw, D. J.
Jones, M. H.
Bergfeld, J.
Swearingen, C. J.
DiFrancesco, A.
Tambiah, J. R.
Hochberg, M.
OSTEOARTHRITIS AND CARTILAGE, 2018, 26 : S293 - S294
[27] RESULTS FROM A 52-WEEK RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2 STUDYOFA NOVEL, INTRA-ARTICULAR WNT PATHWAY INHIBITOR (SM04690) FOR THE TREATMENT OF KNEE OSTEOARTHRITIS
Yazici, Y.
McAlindon, T.
Gibofsky, A.
Lane, N.
Clauw, D.
Grifman, M.
Swearingen, C.
DiFrancesco, A.
Tambiah, J.
Hochberg, M.
JCR-JOURNAL OF CLINICAL RHEUMATOLOGY, 2018, 24 : S137 - S137
[28] THE NOVEL, INTRA-ARTICULAR CLK/DYRK1A INHIBITOR LORECIVIVINT (LOR; SM04690), WHICH MODULATES THE WNT PATHWAY, IMPROVED RESPONDER OUTCOMES IN SUBJECTS WITH KNEE OSTEOARTHRITIS: A POST HOC ANALYSIS FROM A PHASE 2B TRIAL
Yazici, Y.
Kennedy, S.
Swearingen, C.
Tambiah, J.
ANNALS OF THE RHEUMATIC DISEASES, 2020, 79 : 809 - 810
[29] THE NOVEL, INTRA-ARTICULAR CLK/DYRK1A INHIBITOR LORECIVIVINT (LOR; SM04690), WHICH MODULATES THE WNT PATHWAY, IMPROVED RESPONDER OUTCOMES IN SUBJECTS WITH KNEE OSTEOARTHRITIS: A POST HOC ANALYSIS FROM A PHASE 2B TRIAL
Yazici, Yusuf
Kennedy, Sarah
Swearingen, Christopher I.
Tambiah, Jeyanesh
JCR-JOURNAL OF CLINICAL RHEUMATOLOGY, 2020, 26 : 120 - 121
[30] The Novel, Intra-articular CLK/DYRK1A Inhibitor Lorecivivint (LOR; SM04690), Which Modulates the Wnt Pathway, Improved Responder Outcomes in Subjects with Knee Osteoarthritis: A Post Hoc Analysis from a Phase 2b Trial
Yazici, Yusuf
Kennedy, Sarah
Swearingen, Chris
Tambiah, Jeyanesh
ARTHRITIS & RHEUMATOLOGY, 2019, 71

← 1 2 3 4 5 →